{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T03:03:01Z","timestamp":1792292581972,"version":"4.4.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2020,4,30]],"date-time":"2020-04-30T00:00:00Z","timestamp":1588204800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,4,30]],"date-time":"2020-04-30T00:00:00Z","timestamp":1588204800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Microbiol Infect Dis"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1007\/s10096-020-03877-w","type":"journal-article","created":{"date-parts":[[2020,7,8]],"date-time":"2020-07-08T09:03:49Z","timestamp":1594199029000},"page":"1559-1572","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["In vitro activity of omadacycline against pathogens isolated from Mainland China during 2017\u20132018"],"prefix":"10.1007","volume":"39","author":[{"given":"Dong","family":"Dong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yonggui","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingqing","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shi","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Demei","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia A.","family":"Bradford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harald","family":"Reinhart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1285-2978","authenticated-orcid":false,"given":"Fupin","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,4,30]]},"reference":[{"issue":"Supplement_1","key":"3877_CR1","doi-asserted-by":"publisher","first-page":"S6","DOI":"10.1093\/cid\/ciz395","volume":"69","author":"JA Karlowsky","year":"2019","unstructured":"Karlowsky JA, Steenbergen J, Zhanel GG (2019) Microbiology and preclinical review of omadacycline. Clin Infect Dis 69(Supplement_1):S6\u2013S15. https:\/\/doi.org\/10.1093\/cid\/ciz395","journal-title":"Clin Infect Dis"},{"key":"3877_CR2","doi-asserted-by":"publisher","unstructured":"Heidrich CG, Mitova S, Schedlbauer A, Connell SR, Fucini P, Steenbergen JN, Berens C (2016) The novel aminomethylcycline omadacycline has high specificity for the primary tetracycline-binding site on the bacterial ribosome. Antibiotics (Basel) 5(4). https:\/\/doi.org\/10.3390\/antibiotics5040032","DOI":"10.3390\/antibiotics5040032"},{"key":"3877_CR3","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.jgar.2019.02.017","volume":"19","author":"MD Huband","year":"2019","unstructured":"Huband MD, Pfaller MA, Shortridge D, Flamm RK (2019) Surveillance of omadacycline activity tested against clinical isolates from the United States and Europe: results from the SENTRY Antimicrobial Surveillance Programme, 2017. J Glob Antimicrob Resist 19:56\u201363. https:\/\/doi.org\/10.1016\/j.jgar.2019.02.017","journal-title":"J Glob Antimicrob Resist"},{"key":"3877_CR4","doi-asserted-by":"publisher","unstructured":"Stapert L, Wolfe C, Shinabarger D, Marra A, Pillar C (2018) In vitro activities of omadacycline and comparators against anaerobic bacteria. Antimicrob Agents Chemother 62(4). https:\/\/doi.org\/10.1128\/aac.00047-18","DOI":"10.1128\/aac.00047-18"},{"issue":"6","key":"3877_CR5","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1056\/NEJMoa1800170","volume":"380","author":"W O'Riordan","year":"2019","unstructured":"O'Riordan W, Green S, Overcash JS, Puljiz I, Metallidis S, Gardovskis J, Garrity-Ryan L, Das AF, Tzanis E, Eckburg PB, Manley A, Villano SA, Steenbergen JN, Loh E (2019) Omadacycline for acute bacterial skin and skin-structure infections. N Engl J Med 380(6):528\u2013538. https:\/\/doi.org\/10.1056\/NEJMoa1800170","journal-title":"N Engl J Med"},{"issue":"10","key":"3877_CR6","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1016\/s1473-3099(19)30275-0","volume":"19","author":"W O'Riordan","year":"2019","unstructured":"O'Riordan W, Cardenas C, Shin E, Sirbu A, Garrity-Ryan L, Das AF, Eckburg PB, Manley A, Steenbergen JN, Tzanis E, McGovern PC, Loh E (2019) Once-daily oral omadacycline versus twice-daily oral linezolid for acute bacterial skin and skin structure infections (OASIS-2): a phase 3, double-blind, multicentre, randomised, controlled, non-inferiority trial. Lancet Infect Dis 19(10):1080\u20131090. https:\/\/doi.org\/10.1016\/s1473-3099(19)30275-0","journal-title":"Lancet Infect Dis"},{"issue":"6","key":"3877_CR7","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1056\/NEJMoa1800201","volume":"380","author":"R Stets","year":"2019","unstructured":"Stets R, Popescu M, Gonong JR, Mitha I, Nseir W, Madej A, Kirsch C, Das AF, Garrity-Ryan L, Steenbergen JN, Manley A, Eckburg PB, Tzanis E, McGovern PC, Loh E (2019) Omadacycline for community-acquired bacterial pneumonia. N Engl J Med 380(6):517\u2013527. https:\/\/doi.org\/10.1056\/NEJMoa1800201","journal-title":"N Engl J Med"},{"issue":"2","key":"3877_CR8","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.diagmicrobio.2018.01.019","volume":"91","author":"MA Pfaller","year":"2018","unstructured":"Pfaller MA, Rhomberg PR, Huband MD, Flamm RK (2018) Activity of omadacycline tested against Enterobacteriaceae causing urinary tract infections from a global surveillance program (2014). Diagn Microbiol Infect Dis 91(2):179\u2013183. https:\/\/doi.org\/10.1016\/j.diagmicrobio.2018.01.019","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"2","key":"3877_CR9","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.diagmicrobio.2017.10.010","volume":"90","author":"MA Pfaller","year":"2018","unstructured":"Pfaller MA, Rhomberg PR, Huband MD, Flamm RK (2018) Activity of omadacycline tested against Streptococcus pneumoniae from a global surveillance program (2014). Diagn Microbiol Infect Dis 90(2):143\u2013147. https:\/\/doi.org\/10.1016\/j.diagmicrobio.2017.10.010","journal-title":"Diagn Microbiol Infect Dis"},{"key":"3877_CR10","volume-title":"M07-A11 Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically","author":"CLSI","year":"2018","unstructured":"CLSI (2018) M07-A11 Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, Tenth edn. Clinical and Laboratory Standards Institute, Wayne","edition":"Tenth"},{"key":"3877_CR11","unstructured":"CLSI (2020) M100-S30 Performance standards for antimicrobial susceptibility testing. Clinical and Laboratory Standards Institute, Wayne, PA"},{"issue":"4","key":"3877_CR12","doi-asserted-by":"publisher","first-page":"e02431","DOI":"10.1128\/aac.02431-18","volume":"63","author":"D Yin","year":"2019","unstructured":"Yin D, Wu S, Yang Y, Shi Q, Dong D, Zhu D, Hu F (2019) Results from the China Antimicrobial Surveillance Network (CHINET) in 2017 of the in vitro activities of ceftazidime-avibactam and ceftolozane-tazobactam against clinical isolates of Enterobacteriaceae and Pseudomonas aeruginosa. Antimicrob Agents Chemother 63(4):e02431\u2013e02418. https:\/\/doi.org\/10.1128\/aac.02431-18","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"3877_CR13","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.ijantimicag.2012.07.009","volume":"40","author":"S Yezli","year":"2012","unstructured":"Yezli S, Li H (2012) Antibiotic resistance amongst healthcare-associated pathogens in China. Int J Antimicrob Agents 40(5):389\u2013397. https:\/\/doi.org\/10.1016\/j.ijantimicag.2012.07.009","journal-title":"Int J Antimicrob Agents"},{"key":"3877_CR14","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.envint.2017.10.016","volume":"110","author":"M Qiao","year":"2018","unstructured":"Qiao M, Ying G-G, Singer AC, Zhu Y-G (2018) Review of antibiotic resistance in China and its environment. Environ Int 110:160\u2013172. https:\/\/doi.org\/10.1016\/j.envint.2017.10.016","journal-title":"Environ Int"},{"issue":"2","key":"3877_CR15","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/S1473-3099(15)00424-7","volume":"16","author":"Y-Y Liu","year":"2016","unstructured":"Liu Y-Y, Wang Y, Walsh TR, Yi L-X, Zhang R, Spencer J, Doi Y, Tian G, Dong B, Huang X, Yu L-F, Gu D, Ren H, Chen X, Lv L, He D, Zhou H, Liang Z, Liu J-H, Shen J (2016) Emergence of plasmid-mediated colistin resistance mechanism MCR-1 in animals and human beings in China: a microbiological and molecular biological study. Lancet Infect Dis 16(2):161\u2013168. https:\/\/doi.org\/10.1016\/S1473-3099(15)00424-7","journal-title":"Lancet Infect Dis"},{"issue":"11","key":"3877_CR16","doi-asserted-by":"publisher","first-page":"6772","DOI":"10.1021\/acs.est.5b00729","volume":"49","author":"QQ Zhang","year":"2015","unstructured":"Zhang QQ, Ying GG, Pan CG, Liu YS, Zhao JL (2015) Comprehensive evaluation of antibiotics emission and fate in the river basins of China: source analysis, multimedia modeling, and linkage to bacterial resistance. Environ Sci Technol 49(11):6772\u20136782. https:\/\/doi.org\/10.1021\/acs.est.5b00729","journal-title":"Environ Sci Technol"},{"issue":"1","key":"3877_CR17","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/1744-8603-2-6","volume":"2","author":"R Zhang","year":"2006","unstructured":"Zhang R, Eggleston K, Rotimi V, Zeckhauser RJ (2006) Antibiotic resistance as a global threat: evidence from China, Kuwait and the United States. Glob Health 2(1):6. https:\/\/doi.org\/10.1186\/1744-8603-2-6","journal-title":"Glob Health"},{"issue":"3","key":"3877_CR18","doi-asserted-by":"publisher","first-page":"115","DOI":"10.3390\/antibiotics8030115","volume":"8","author":"X Zhen","year":"2019","unstructured":"Zhen X, St\u00e5lsby Lundborg C, Sun X, Hu X, Dong H (2019) The clinical and economic impact of antibiotic resistance in China: a systematic review and meta-analysis. Antibiotics 8(3):115. https:\/\/doi.org\/10.3390\/antibiotics8030115","journal-title":"Antibiotics"},{"issue":"1","key":"3877_CR19","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.diagmicrobio.2018.11.010","volume":"94","author":"AC Fluit","year":"2019","unstructured":"Fluit AC, van Gorkum S, Vlooswijk J (2019) Minimal inhibitory concentration of omadacycline and doxycycline against bacterial isolates with known tetracycline resistance determinants. Diagn Microbiol Infect Dis 94(1):78\u201380. https:\/\/doi.org\/10.1016\/j.diagmicrobio.2018.11.010","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"2","key":"3877_CR20","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1128\/aac.01242-13","volume":"58","author":"AB Macone","year":"2014","unstructured":"Macone AB, Caruso BK, Leahy RG, Donatelli J, Weir S, Draper MP, Tanaka SK, Levy SB (2014) In vitro and in vivo antibacterial activities of omadacycline, a novel aminomethylcycline. Antimicrob Agents Chemother 58(2):1127\u20131135. https:\/\/doi.org\/10.1128\/aac.01242-13","journal-title":"Antimicrob Agents Chemother"},{"key":"3877_CR21","unstructured":"NUZYRA (omadacycline) prescribing information. (2019). https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/209816_209817lbl.pdf."},{"issue":"3","key":"3877_CR22","doi-asserted-by":"publisher","first-page":"e02262","DOI":"10.1128\/aac.02262-18","volume":"63","author":"CG Carvalhaes","year":"2019","unstructured":"Carvalhaes CG, Huband MD, Reinhart HH, Flamm RK, Sader HS (2019) Antimicrobial activity of omadacycline tested against clinical bacterial isolates from hospitals in Mainland China, Hong Kong, and Taiwan: results from the SENTRY Antimicrobial Surveillance Program (2013 to 2016). Antimicrob Agents Chemother 63(3):e02262\u2013e02218. https:\/\/doi.org\/10.1128\/aac.02262-18","journal-title":"Antimicrob Agents Chemother"},{"issue":"7","key":"3877_CR23","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1111\/1469-0691.12705","volume":"20","author":"CJ Chen","year":"2014","unstructured":"Chen CJ, Huang YC (2014) New epidemiology of Staphylococcus aureus infection in Asia. Clin Microbiol Infect 20(7):605\u2013623. https:\/\/doi.org\/10.1111\/1469-0691.12705","journal-title":"Clin Microbiol Infect"},{"issue":"11","key":"3877_CR24","doi-asserted-by":"publisher","first-page":"e27328","DOI":"10.1371\/journal.pone.0027328","volume":"6","author":"J Du","year":"2011","unstructured":"Du J, Chen C, Ding B, Tu J, Qin Z, Parsons C, Salgado C, Cai Q, Song Y, Bao Q, Zhang L, Pan J, Wang L, Yu F (2011) Molecular characterization and antimicrobial susceptibility of nasal Staphylococcus aureus isolates from a Chinese medical college campus. PLoS One 6(11):e27328. https:\/\/doi.org\/10.1371\/journal.pone.0027328","journal-title":"PLoS One"},{"issue":"1","key":"3877_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.diagmicrobio.2009.12.006","volume":"67","author":"D Wu","year":"2010","unstructured":"Wu D, Wang Q, Yang Y, Geng W, Wang Q, Yu S, Yao K, Yuan L, Shen X (2010) Epidemiology and molecular characteristics of community-associated methicillin-resistant and methicillin-susceptible Staphylococcus aureus from skin\/soft tissue infections in a children\u2019s hospital in Beijing, China. Diagn Microbiol Infect Dis 67(1):1\u20138. https:\/\/doi.org\/10.1016\/j.diagmicrobio.2009.12.006","journal-title":"Diagn Microbiol Infect Dis"}],"container-title":["European Journal of Clinical Microbiology & Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-020-03877-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10096-020-03877-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-020-03877-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,30]],"date-time":"2021-04-30T00:28:43Z","timestamp":1619742523000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10096-020-03877-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,30]]},"references-count":25,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["3877"],"URL":"https:\/\/doi.org\/10.1007\/s10096-020-03877-w","relation":{},"ISSN":["0934-9723","1435-4373"],"issn-type":[{"value":"0934-9723","type":"print"},{"value":"1435-4373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,30]]},"assertion":[{"value":"12 February 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Antimicrobial development specialists, LLC, was contracted to during 2019 to perform services for Boston Pharma, Carb-X, Colgate Palmolive, ContraFect Corp., Emergent Biosciences, Entasis Therapeutics, EXDA, Nabriva, NacuGen, Novartis, RecreoPharma, Sihuan Pharmaceutical, SuperTrans Medical, Tetraphase, Theravance, University of Waterloo, Wellcome Trust, X-Biotix, and Zai Labs.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was approved by the Institutional Review Board of Huashan Hospital, Fudan University (Number: 2018-349).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}]}}